61809-40-3

Usage

Uses

Used in Pharmaceutical Industry:
2-Bromo-5-methoxy-4-methylbenzoic acid is used as a synthetic intermediate for the development of various pharmaceuticals. Its unique structure and reactivity allow for the creation of new drug molecules with potential therapeutic applications.
Used in Agrochemical Industry:
In the agrochemical sector, 2-Bromo-5-methoxy-4-methylbenzoic acid serves as a key building block in the synthesis of pesticides and other agrochemicals. Its chemical properties enable the production of effective compounds for crop protection and enhancement of agricultural yields.
Used in Material Science:
2-Bromo-5-methoxy-4-methylbenzoic acid also finds applications in the field of material science. Its versatile chemical structure allows for the development of new materials with specific properties, such as improved stability, reactivity, or other desired characteristics for various industrial applications.

InChI:InChI=1/C9H9BrO3/c1-5-3-7(10)6(9(11)12)4-8(5)13-2/h3-4H,1-2H3,(H,11,12)

Upstream product

• 7151-68-0 3-methoxy-p-toluic acid 

Downstream Products

• 87808-28-4 2-bromo-5-methoxy-4-methyl-benzoic acid methyl ester 
• 90972-30-8 2-amino-5-methoxy-4-methyl-benzoic acid 
• 1429776-75-9 5-methoxy-4-methyl-2-(2H-1 ,2,3-triazol-2-yl)benzoic acid 
• 1597527-77-9 5-methoxy-4-methyl-2-pyrimidin-2-ylbenzoic acid hydrochloride 
• 1597527-79-1 methyl 5-methoxy-4-methyl-2-(pyrimidin-2-yl)benzoate 
• 1597522-15-0 (5-methoxy-4-methyl-2-pyrimidin-2-ylphenyl)-{(S)-2-[3-(2-trifluoromethoxyphenyl)-[1,2,4]oxadiazol-5-yl]pyrrolidin-1-yl}methanone 
• 1138220-72-0 6-hydroxy-5-methylisoindolin-1-one 
• 1138220-75-3 methyl 2-cyano-5-methoxy-4-methylbenzoate 

Relevant academic research and scientific papers

Oxadiazole Derivatives as Dual Orexin Receptor Antagonists: Synthesis, Structure–Activity Relationships, and Sleep-Promoting Properties in Rats

The orexin system plays an important role in the regulation of wakefulness. Suvorexant, a dual orexin receptor antagonist (DORA) is approved for the treatment of primary insomnia. Herein, we outline our optimization efforts toward a novel DORA. We started our investigation with rac-[3-(5-chloro-benzooxazol-2-ylamino)piperidin-1-yl]-(5-methyl-2-[1,2,3]triazol-2-ylphenyl)methanone (3), a structural hybrid of suvorexant and a piperidine-containing DORA. During the optimization, we resolved liabilities such as chemical instability, CYP3A4 inhibition, and low brain penetration potential. Furthermore, structural modification of the piperidine scaffold was essential to improve potency at the orexin 2 receptor. This work led to the identification of (5-methoxy-4-methyl-2-[1,2,3]triazol-2-ylphenyl)-{(S)-2-[5-(2-trifluoromethoxyphenyl)-[1,2,4]oxadiazol-3-yl]pyrrolidin-1-yl}methanone (51), a potent, brain-penetrating DORA with in vivo efficacy similar to that of suvorexant in rats.

ASK1 INHIBITOR COMPOUNDS AND USES THEREOF

Described herein are compounds, including pharmaceutically acceptable salts, solvates, metabolites, prodrugs thereof, methods of making such compounds, pharmaceutical compositions comprising such compounds, and methods of using such compounds to treat non

NOVEL BENZYLAMINO SUBSTITUTED QUINAZOLINES AND DERIVATIVES AS SOS1 INHIBITORS

The present invention encompasses compounds of formula (I), wherein the groups R1 to R7 have the meanings given in the claims and specification, their use as inhibitors of SOS1, pharmaceutical compositions which contain compounds of this kind and their use as medicaments/medical uses, especially as agents for treatment and/or prevention of oncological diseases.

2-(1,2,3-TRIAZOL-2-YL)BENZAMIDE AND 3-(1,2,3-TRIAZOL-2-YL)PICOLINAMIDE DERIVATIVES AS OREXIN RECEPTOR ANTAGONISTS

The present invention relates to 2-(1,2,3-triazol-2-yl)benzamide and 3-(1,2,3-triazol-2-yl)picolinamide derivatives of formula (I) wherein Ar1, Q, and R1 to R5 are as described in the description, to their preparation, to

OREXIN RECEPTOR ANTAGONISTS WHICH ARE [ORTHO BI (HETERO )ARYL]-[2-(META BI (HETERO )ARYL)-PYRROLIDIN-1-YL]-METHANONE DERIVATIVES

The present invention relates to [ortho bi-(hetero-)aryl]-[2-(meta bi-(hetero-)aryl)-pyrrolidin-1-yl]- methanone derivatives of formula (I) wherein R, and the rings A1 A2 and A3 are as described in the description, to pharmaceutically acceptable salts thereof, to their preparation, to pharmaceutical compositions containing one or more compounds of formula (I), and to their use as pharmaceuticals, especially to their use as orexin receptor antagonists.

AZETIDINE AMIDE DERIVATIVES AS OREXIN RECEPTOR ANTAGONISTS

The present invention relates to azetidine amide derivatives derivatives of formula (I) wherein rings A1 A2 and A3 are as described in the description, to pharmaceutically acceptable salts thereof, to their preparation, to

2-(1,2,3-TRIAZOL-2-YL)BENZAMIDE AND 3-(1,2,3-TRIAZOL-2-YL)PICOLINAMIDE DERIVATIVES AS OREXIN RECEPTOR ANTAGONISTS

The present invention relates to 2-(1,2,3-triazol-2-yl)benzamide and 3-(1,2,3-triazol-2- yl)picolinamide derivatives of formula (I) Formula (I) wherein Ar1, Q, and R1 to R5 are as described in the description, to their pre

Synthesis of methyl-, fluoro-, and chloro-substituted 6-hydroxyisoindolin-1-ones

The synthesis of a series of methyl-, fluoro-, and chloro-substituted 6-hydroxyisoindolin-1-ones is described.